Download Files:

Crizotinib

SKU T1661-1 mL * 10 mM (in DMSO) Category Small Compound Brand: TargetMol

Price range: 74 CAD through 253 CAD

For Research Use Only (RUO). This product is sold strictly for laboratory research use. Not for human or veterinary consumption, therapeutic, or diagnostic use.For sale to research organizations and laboratories only; not for patients or for personal use.

Size

1 mL * 10 mM (in DMSO)10 mg 100 mg 200 mg 25 mg 50 mg 500 mg

Clear

Products Details

Product Description

– Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinase inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptors.

For Research Use Only (RUO). This product is sold strictly for laboratory research use only. Not for human or veterinary consumption, therapeutic, or diagnostic use. Any pharmacological, therapeutic, cosmetic, or biological effects described above are provided as research context only and do not represent intended or approved uses of this product.

Web ID

– T1661

Storage Temperature

– -20℃

Shipping

– Blue Ice

Molecular Formula

– C21H22Cl2FN5O

Citations

– 1. Yan H, Wu W, Hu Y, et al.Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis.Nature Communications.2023, 14(1): 2756. 2. Li P, Jia C, Fan Z, et al.Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations.Acta Pharmaceutica Sinica B.2023 3. Zou X, Zeng M, Zheng Y, et al.Comparative Study of Hydroxytyrosol Acetate and Hydroxytyrosol in Activating Phase II Enzymes.Antioxidants.2023, 12(10): 1834. 4. Jiao D, Chen Y, Liu X, et al.Targeting MET endocytosis or degradation to overcome HGF-induced gefitinib resistance in EGFR-sensitive mutant lung adenocarcinoma.Biochemical and Biophysical Research Communications.2023 5. Yu J, Zhang L, Peng J, et al. Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways. Biochemical pharmacology. 2022, 195: 114864. 6. Arechederra M, Bazai S K, Abdouni A, et al. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. Journal of Hepatology. 2021, 74(4): 893-906. 7. Yang Y, Huang J, Xie N, et al. lincROR influences the stemness and crizotinib resistance in eMl–alK+ non-small-cell lung cancer cells. OncoTargets and Therapy. 2018 Jun 22;11:3649-3657 8. Tao J, Tu Y, Liu P, et al. Detection of colorectal cancer using a small molecular fluorescent probe targeted against c-Met. Talanta. 2021: 122128. 9. Hu Y, Zhang X, Zhao Z, et al. Keratinocytes apoptosis contributes to crizotinib induced-erythroderma. Toxicology Letters. 2019 10. Zheng Y D, Zhong T, Wu H, et al. Crizotinib Shows Antibacterial Activity against Gram-Positive Bacteria by Reducing ATP Production and Targeting the CTP Synthase PyrG. Microbiology Spectrum. 2022: e00884-22

References

– Zou HY, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007 May 1;67(9):4408-17.

CAS Number

– 877399-52-5

Molecular Weight

– C21H22Cl2FN5O

Compound Purity

– 0.9935

SMILES

– O([C@H](C)C1=C(Cl)C(F)=CC=C1Cl)C2=CC(C3=CN(N=C3)C4CCNCC4)=CN=C2N

Target

– Aryl Hydrocarbon Receptor

Pathway

– Angiogenesis|||Tyrosine Kinase/Adaptors|||Immunology/Inflammation|||Autophagy

Product type

– Small Compound

Booklet

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.